For example, a previous trial conducted in Japan had recruited 45 patients with Stage I B1-IV B carcinoma of the cervix and found that there were no significant differences in ERCC1 expression between the low and high sensitivity to nedaplatin groups (P=0.079) (11). This evidence concerns the gene ERCC1 and cervical carcinoma.